Latest HER2/neu Stories
WORCESTER, Mass. and TORONTO, Feb.
NEW YORK, Feb.
Analysis of Phase I Trial indicates Safety and positive immune response data in 21 of 21 patients administered Folate Receptor Alpha Vaccine for breast and ovarian cancers SEATTLE,
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
SAN DIEGO, Dec. 12, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc.
Studies Using Caris Molecular Intelligence(TM) Identify Standard as well as Novel Therapeutic Options Based on Molecular Characterization of Individual Patients' Tumors IRVING, Texas,
The cancer drug eribulin, originally developed from sea sponges, could give women with advanced triple negative breast cancer an average of five extra months of life
WORCESTER, Mass. and TORONTO, Oct.
RnRMarketResearch.com adds “Perjeta & Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023” to its store.
DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.